ABVX Abivax SA
$87.41
▼ 5.4%Updated Oct 16, 2:25 PM ET
Report Card
ABVX at a glance — five pillars scored 0–100 from real filed financials.
How the 0–100 rating is calculatedOverall: Weak · 35/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Price — Past Year
▲ Up 1728.0% in the year to Jul 6, 2026
Key Metrics
Market Cap
$11.63B
P/E
—
Forward P/E (est.)
—
ROE
-51.7%
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
-2.1%
Debt / Equity
0x
ROIC
-40.0%
Interest Coverage
—
Current Ratio
8.75x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
35/100
Business Overview
Abivax SA (ABVX) is a large-cap NASDAQ-listed company in the Biotechnology industry, within the Health Care sector, with a market value around $11.63B.
In its latest reported year it generated about $6.05M in revenue and posted a net loss of $362.99M.
Our model rates ABVX Weak (35/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Economic Moat
Evidence of durable competitive advantage in the filed financials (5 years of history).
Profit margins and economic moats, explainedThe numbers don't show a durable competitive advantage — margins, growth, or returns on capital have been unstable or thin. Great returns are still possible; they just aren't protected.
grew in 2 of the last 4 year-over-year periods
positive in 0 of 5 years
-40.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical Analysis (Educational)
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ABVX's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ABVX trades near $87.41, below its 50-day average ($112.92) and 200-day average ($112.34). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 83 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ABVX's is $10.45 (~12.0% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. In the month to Jul 6, 2026, ABVX found buyers near $74.79 (support) and sellers near $147.98 (resistance); its 52-week range then was $7.64–$148.83. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.4× the 20-day average — lighter than usual, so the move carries less conviction. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. The indicators were last computed on Jul 6, 2026; the price is current.
Revenue Growth
Profitability
Gross Margin
—
Operating Margin
-4393.9%
Net Margin
-6001.8%
ROE
-51.7%
Abivax SA keeps about n/a of each sales dollar as net profit. Return on equity is -51.7% and return on invested capital about -40.0%. The company is currently unprofitable on a net basis.
Debt Analysis
Total Debt
$33.25M
Net Debt
-$524.77M
Net cash position
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 8.8x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $33.25M of total debt against $558.02M of cash.
Cash Flow Analysis
Operating CF
-$174.02M
Free Cash Flow
-$174.17M
FCF Margin
-2879.8%
In the latest year Abivax SA produced about -$174.02M of operating cash flow but negative free cash flow as it invested heavily. That is a free-cash-flow yield of about -2.1% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
Valuation Analysis
P/E
—
P/S
1,019,626x
P/B
19.86x
EV / EBITDA
—
ABVX trades at n/a trailing earnings, 1019626.0x sales, and 19.9x book value. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Metrics vs. Sector Range
Where ABVX sits versus the Health Care companies we cover.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
Sector Peer Comparison
How ABVX stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
Among the 83 rated Health Care companies we cover, ABVX ranks #68 by our overall rating.
P/E vs sector
—
median 26.1x
ROE vs sector
-51.7%
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#68
of 83 rated
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.
5-Year Projection Model
Project revenue → earnings → price. Edit the assumptions to build your own case.
What drives this projection, and its limits2030 scenario price range (Base Case)
$0.02 – $0.04
vs. $87.41 today · implied CAGR -81% – -79%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $6.53M | $7.05M | $7.62M | $8.23M | $8.89M |
| Net income | $195.96K | $211.63K | $228.56K | $246.85K | $266.59K |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Share price (low) | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 |
| Share price (high) | $0.03 | $0.03 | $0.03 | $0.04 | $0.04 |
| CAGR (low–high) | -100% / -100% | -99% / -98% | -94% / -93% | -87% / -86% | -81% / -79% |
Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.
Bull Case
The case for ABVX:
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
Bear Case
The case against ABVX:
- Limited free cash flow at today's price.
- Our model's overall read is Weak (35/100).
Key Risks
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
Investment Thesis
On balance, the fundamentals screen weakly: Abivax SA is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at n/a earnings, which our model scores Weak (35/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 14 Wall Street analysts covering ABVX recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
ABVX's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K
In the Idea Lab
ABVX — frequently asked questions
Is ABVX a good stock to buy?
We don't give buy or sell advice. Our model rates Abivax SA Weak (35/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is ABVX's rating on The Stocks School?
Abivax SA currently scores 35/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does ABVX's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Abivax SA's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for ABVX calculated?
It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.
Is this ABVX analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell ABVX. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.